English Language & Literature

Case Based Factual Passage

Class 10

Multiple Choice Questions Type

Case Based Factual Passage 01

Read the passage and answer the questions that follow:

  1. The Indian pharma industry is flourishing overseas, touching almost every part of the world. With low cost, speed and high-quality advantage, India is gearing up to become the hub for contract research and manufacturing. Having a competitive edge is, one thing and maintaining it is another. Canada provides tax benefits up to 6% for research carried out within the country. Others like Korea and China without a large pool of scientists make up by facilitating foreign research in every conceivable way.
  2. India does not do any of this and faces many hurdles – diseases that it has been inflicted with since independence like Malaria and TB while Indian companies have only focused on reverse engineering blockbuster drugs from MNCs, overseas scientists have displayed little interest in researching sub-continent specific diseases as there are more profits and public interest in lifestyle drugs such as obesity which in turn fund their research. In the interest of Indian research industry, a decision must be taken quickly on the implementation of data protection laws.
  3. India is one of the few countries where data exclusivity provisions are not prevalent. Data protection is a contentious issue, wholly debated by the government and the industry. A pharma company wishing to market a drug is required to submit data to the drug controller to show that the drug is both effective and safe. The first (originator) company that makes the application for marketing approval has to submit its data relating to the clinical trials to the drug controller, who once satisfied that the drug is safe and effective will register it. Another drug company wishing to market the same drug only requires to show a bio-equivalence company. Thus, as per the prevailing laws, the regulator in India can rely on an innovator’s data to approve the competitor’s product.
  4. While the system in general is responsible for maintaining the necessary secrecy, it is not accountable for the same—the competitor gets an unfair advantage over the innovator even when he is clandestinely abusing an innovator’s intellectual property. Consequently research-based pharma companies are being forced to undertake vital clinical trials abroad. Huge expenditures are incurred overseas, draining precious foreign exchange when this could be done at home at a fraction of the cost.

Question.1.
The Indian pharma companies prefer to research in _______. Choose the correct option.

(a) reverse engineering discontinued drugs from MNCs.
(b) sub-continent specific diseases and their cure.
(c) cure for malaria and tuberculosis.
(d) reverse engineering blockbuster drugs from MNCs.

(d) reverse engineering blockbuster drugs from MNCs.

Question.2.
Select the option that is true for the two statements given below.
(1) The competitor gets an unfair advantage over the innovator.
(2) The regulator in India can rely on an innovator’s data to approve the competitor’s product.

(a) (2) is the reason for (1).
(b) (1) contradicts (2).
(c) (2) is independent of (1).
(d) (2) is the result of (1).

(a) (2) is the reason for (1)

Question.3.
Select the option that gives the correct meaning of the following statement.
While the system in general is responsible for maintaining the necessary secrecy, it is not accountable for the same.”

(a) The system assures to safeguard intellectual properties of innovators at all cost.
(b) The system controls the intellectual properties but cannot guarantee if it gets copied.
(c) The system is not responsible for registering intellectual properties but protects them.
(d) The innovators can rely on the system because it assures the secrecy of their intellectual property.

(b) The system controls the intellectual properties but cannot guarantee if it gets copied.

Question.4.
According to the data, overseas scientists don’t research on diseases that affect third world countries because____.

(a) they lack proper funds and knowledge for research in that field.
(b) there are more profits and public interest in lifestyle drugs.
(c) sub-continental diseases can be deadly hence riskier to work with.
(d) other scientists are already doing research on those diseases.

(b) there are more profits and public interest in lifestyle drugs.

Question.5.
Select the option listing what the given sentence refers to.
Another drug company wishing to market the same drug only requires to show a bio-equivalence company.’
(1) The other drug company has to innovate from the start.
(2) The other company can easily market someone else’s drug.
(3) The other drug company can easily copy the formula.
(4) The innovator can do almost nothing to stop plagiarism.
(5) The innovator can stop other companies from selling their drug.

(a) (1), (3) and (4)
(b) (2), (3) and (5)
(c) (2), (4) and (5)
(d) (2), (3) and (4)

(d) (2), (3) and (4)

Question.6.
How do Korea and China excel in the research field even without a large pool of scientists?

(a) by facilitating foreign research.
(b) by avoiding foreign research.
(c) by copying foreign research material.
(d) by paying large sums of money to buy the ranks.

(a) by facilitating foreign research

Question.7.
The passage discusses that the Indian pharma industry is flourishing overseas because_______.
Select the correct option.

(a) Indian pharma companies are spending money to reverse engineer already successful drugs.
(b) India provides low cost, speed and high-quality advantage in research and manufacturing.
(c) Indian pharma industry promises secrecy when it comes to protecting new innovations.
(d) Indian produced drugs cannot be used in foreign market because of unregulated protocol.

(b) India provides low cost, speed and high-quality advantage in research and manufacturing.

Question.8.
Choose the correct option to answer the following:
According to paragraph 4, ‘Huge expenditures are incurred overseas, draining precious foreign exchange’. This is so because:

(a) research-based pharma companies are allowed to undertake vital clinical trials at home.
(b) research-based pharma companies take bribes to undertake vital clinical trials.
(c) research-based pharma companies are being forced to undertake vital clinical trials abroad.
(d) research-based pharma companies don’t have to undertake vital clinical trials for safety.

(c) research-based pharma companies are being forced to undertake vital clinical trials abroad.

Leave a Comment

Your email address will not be published.

error: Content is protected !!